{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:16:00Z","timestamp":1793754960608,"version":"4.6.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Acute Kidney Injury (AKI) is a common clinical syndrome characterized by an abrupt decline in the glomerular filtration rate (GFR), which can cause severe alterations in blood volume and acid-base balance. Drug-Induced Acute Kidney Injury (DI-AKI) is associated with exposure to nephrotoxic medications, particularly among hospitalized patients. Adverse drug reactions comprises type A and type B reactions. Type A reactions are predictable based on the pharmacology of the substance, dose-dependent, and manifest as Acute Tubular Necrosis (ATN). Type B reactions are unpredictable, idiosyncratic, not dose-dependent, and manifest as Acute Interstitial Nephritis (AIN), Crystal-Induced Nephropathy, among others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate DI-AKI incidence, identify the main associated drugs and the pathophysiological mechanism of the observed injury, analyze prognostic factors associated with unfavorable outcomes, and compare the outcomes of death and the need for Acute Kidney Support Therapy (AKST) between patients with DI-AKI vs. AKI due to other etiologies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study conducted at the Hospital das Cl\u00ednicas of the Faculty of Medicine of Botucatu \u2013 UNESP (HC-FMB), using data from patients hospitalized between January 2016 and April 2022 and followed, via consultation, by the AKI-Nephrology team. Inclusion criteria: diagnosis of AKI and Chronic Kidney Disease (CKD) with superimposed AKI. Exclusion criteria: patients under 18\u2009years old or on chronic Renal Replacement Therapy. AKI was diagnosed based on creatinine increase as established by KDIGO 2012. Data were presented as mean and standard deviation or median with interquartile range and frequency. Statistical significance was set at 5% (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Comparative analyses were performed using the Chi-Square test for categorical variables and the T-test for continuous variables. Subsequently, logistic regression was performed to identify factors associated with the need for AKST and death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,398 patients were analyzed, most of them males (61.4%), with a mean age of 64\u2009years \u00b114.4\u2009years. The most prevalent etiology of AKI was Mixed Ischemic + Septic AKI (28%). DI-AKI was a significant cause of AKI (19.3%). Of these, 25.2% were isolated DI-AKI and 74.8% were Mixed DI-AKI\u2009+\u2009Ischemia and\/or Sepsis. Among patients with DI-AKI, the mean age was 61.15\u2009\u00b1\u200915.26, males were the most frequent, the majority were not subjected to AKST and survived. Most of these patients were hospitalized in the ward, did not need vasoactive drugs, nor did they use mechanical ventilation. DI-AKI showed lower severity and mortality compared to other AKI etiologies but had a similar need for AKST (26.3% vs. 35.4%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05 and 31.8% vs. 36.8%, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05). Most nephrotoxic drugs caused type A reactions, with Vancomycin being the primary nephrotoxin. Among drugs associated with DI-AKI, Vancomycin was associated with a higher need for AKST and death, while Amphotericin B was associated with a lower risk of AKST and death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although the mortality rate is lower among DI-AKIs compared to other AKI etiologies, the need for AKST was similar. Therefore, it is recommended that DI-AKI be recognized early to enable dose reduction or even drug suspension, depending on the type of reaction, to reduce healthcare costs and improve clinical outcomes for patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1459170","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:50:57Z","timestamp":1730177457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors"],"prefix":"10.3389","volume":"11","author":[{"given":"Georgia","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Repetti","family":"Pacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welder","family":"Zamoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Luis","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.kint.2019.05.026","article-title":"Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment","volume":"96","author":"Peerapornratana","year":"2019","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug Nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCC.0000000000000453","article-title":"Drug-induced kidney disease in the ICU: mechanisms, susceptibility, diagnosis and management strategies","volume":"23","author":"Awdishu","year":"2017","journal-title":"Curr Opin Crit Care"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R's of drug induced nephrotoxicity","author":"Awdishu","year":"2017","journal-title":"BMC Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000510455","article-title":"Drug-induced hospital-acquired acute kidney injury in China: a multicenter cross-sectional survey","volume":"7","author":"Liu","year":"2021","journal-title":"Kidney Dis"},{"key":"ref6","first-page":"744","article-title":"Analysis of drug-induced acute renal failure in Shanghai","volume":"89","author":"Che","year":"2009","journal-title":"Zhonghua yi xue za zhi"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0177460","DOI":"10.1371\/journal.pone.0177460","article-title":"A prospective study of the demographics, management and outcome of patients with acute kidney injury in Cape Town, South Africa","volume":"12","author":"Dlamini","year":"2017","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clinical journal of the American Society of Nephrology: JASN vol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/bmj.n2233","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration","volume":"375","author":"Skrivankova","year":"2021","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"ref12","first-page":"1","article-title":"Kdigo 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"key":"ref14","first-page":"3","article-title":"Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment","volume":"9","author":"Krishnan","year":"2015","journal-title":"Iran J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","article-title":"Amphotericin B-induced nephrotoxicity: a review","volume":"12","author":"Fanos","year":"2000","journal-title":"J chemo"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000185314","article-title":"Easy and early prognosis in acute tubular necrosis: a forward analysis of 228 cases","volume":"51","author":"Lia\u00f1o","year":"2004","journal-title":"Nephron"},{"key":"ref17","article-title":"Stata 8.0. Stata Statistical Software","year":"2004"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.chest.2023.03.046","article-title":"A large-scale multicenter retrospective study on nephrotoxicity associated with empiric broad-Spectrum antibiotics in critically ill patients","volume":"164","author":"Chen","year":"2023","journal-title":"Chest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.chest.2023.05.009","article-title":"Does vancomycin-piperacillin-Tazobactam cause Pseudo-AKI, true nephrotoxicity, or both?","volume":"164","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0217908","DOI":"10.1371\/journal.pone.0217908","article-title":"Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit","volume":"14","author":"Kang","year":"2019","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e006989","DOI":"10.1136\/bmjopen-2014-006989","article-title":"The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis","volume":"5","author":"Zhang","year":"2015","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/phar.2152","article-title":"Drug-associated acute kidney injury identified in the United States Food and Drug Administration adverse event reporting system database","volume":"38","author":"Welch","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2215\/CJN.08300813","article-title":"Acute respiratory distress syndrome and risk of AKI among critically ill patients","volume":"9","author":"Darmon","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"Welty","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Degatta","year":"1996","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1459170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:51:00Z","timestamp":1730177460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1459170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":27,"alternative-id":["10.3389\/fmed.2024.1459170"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1459170","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"article-number":"1459170"}}